Equities Analysts Set Expectations for LAB Q1 Earnings

Standard BioTools Inc. (NASDAQ:LAB) – Equities researchers at KeyCorp issued their Q1 2025 EPS estimates for shares of Standard BioTools in a research report issued on Wednesday, February 26th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.06) per share for the quarter. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Standard BioTools’ current full-year earnings is ($0.29) per share.

Standard BioTools Price Performance

Shares of Standard BioTools stock opened at $1.06 on Monday. The company has a market capitalization of $394.59 million, a P/E ratio of -1.49 and a beta of 1.57. The business has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.79. Standard BioTools has a 1 year low of $0.99 and a 1 year high of $3.04.

Hedge Funds Weigh In On Standard BioTools

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its position in Standard BioTools by 188.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after purchasing an additional 1,597,728 shares during the last quarter. State Street Corp increased its position in Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock worth $10,606,000 after acquiring an additional 1,157,984 shares during the period. Barclays PLC boosted its stake in shares of Standard BioTools by 13.2% in the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after buying an additional 377,195 shares during the period. Geode Capital Management LLC raised its stake in Standard BioTools by 2.3% in the third quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock valued at $13,415,000 after purchasing an additional 154,848 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Standard BioTools by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock valued at $270,000 after acquiring an additional 9,995 shares during the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

Insider Activity at Standard BioTools

In other news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were bought at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the acquisition, the director now directly owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. This trade represents a 8.92 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 53.10% of the stock is owned by insiders.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.